Carl Gauthier, MD
Rheumatology · Hammond, LANPI 1649460239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,319 of the $218,786 with a category attached, or 85.2%. 30 manufacturers reported payments, led by AbbVie at 45.8% of the total. Among rheumatology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 721 payments — averaging $303.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$100K
- Amgen$64K
- Novartis$18K
- Regeneron Healthcare Solutions, Inc.$11K
- Bristol Myers Squibb$11K
- E.r. Squibb & Sons, L.L.C.$7K
- plus $8K from 24 others
What the payments were for
- Consulting fees$9,1934%
- Speaking & faculty fees$186,31985%
- Travel & lodging$9,2034%
- Food & beverage$13,7336%
- Education$3380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 245 | $100,200 |
| Amgen(2 entities) | 161 | $63,998 |
| Novartis | 51 | $17,775 |
| Regeneron Healthcare Solutions, Inc. | 29 | $11,413 |
| Bristol Myers Squibb | 26 | $10,939 |
| E.r. Squibb & Sons, L.L.C. | 14 | $6,549 |
| Sanofi | 4 | $4,369 |
| UCB, Inc. | 46 | $813 |
| Johnson & Johnson | 18 | $444 |
| Pfizer | 25 | $411 |
| Lilly USA, LLC | 22 | $342 |
| GSK | 18 | $290 |
| Mallinckrodt Enterprises LLC | 13 | $213 |
| Mallinckrodt Hospital Products Inc. | 4 | $136 |
| Genentech USA, Inc. | 8 | $135 |
| Fresenius Kabi USA, LLC | 6 | $122 |
| Organon | 5 | $90 |
| Radius Health, Inc. | 4 | $88 |
| Hikma Pharmaceuticals USA | 4 | $82 |
| AstraZeneca | 3 | $71 |
| Antares Pharma, Inc. | 4 | $67 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $36 |
| Oyster Point Pharma, Inc. | 1 | $30 |
| Valinor Pharma, LLC | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Sandoz | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$218,786 in reported general payments places this provider in the 95th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 348 | $2,777,625 |
| RinvoqUpadacitinib | 191 | $1,282,806 |
| Enbrel SureclickEtanercept | 91 | $780,969 |
| EnbrelEtanercept | 62 | $506,634 |
| Xeljanz XrTofacitinib Citrate | 68 | $427,746 |
| OtezlaApremilast | 80 | $398,888 |
| Skyrizi PenRisankizumab-Rzaa | 18 | $397,731 |
| Humira(Cf)Adalimumab | 30 | $317,068 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 40 | $302,073 |
| BenlystaBelimumab | 58 | $286,563 |
| Cosentyx Sensoready PenSecukinumab | 23 | $200,043 |
| XeljanzTofacitinib Citrate | 18 | $110,982 |
| Actemra ActpenTocilizumab | 26 | $107,672 |
| Orencia ClickjectAbatacept | 18 | $103,601 |
| Humira PenAdalimumab | 14 | $97,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Savella, Linzess, Restasis | $100,200 | $1,671,948321 claims |
| AmgenEnbrel, Otezla, Prolia | $63,998 | $949,728167 claims |
| GSKBenlysta | $290 | $286,56358 claims |
| PfizerXeljanz, Lyrica | $411 | $117,88230 claims |
| SanofiKevzara | $4,369 | $65,88515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Hammond
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Agnes SolonAlexandria$123K
- Randall BeylBaton Rouge$112K
- Frankie PedigoShreveport$98K
- Lesley SaketkooNew Orleans$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.